Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Maryam Soleimani Dodaran"'
Autor:
Maryam Soleimani Dodaran, Simone Borgoni, Emre Sofyalı, Pernette J. Verschure, Stefan Wiemann, Perry D. Moerland, Antoine H. C. van Kampen
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
Abstract Background Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance t
Externí odkaz:
https://doaj.org/article/05e1012ebaf343358c57d489aa9794d1
Autor:
Emre Sofyalı, Maryam Soleimani Dodaran, Perry D. Moerland, Antoine H. C. van Kampen, Pernette J. Verschure, Simone Borgoni, Stefan Wiemann
Publikováno v:
BMC Cancer
BMC Cancer, 20:676. BioMed Central
BMC cancer, 20(1):676. BioMed Central
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
BMC Cancer, 20:676. BioMed Central
BMC cancer, 20(1):676. BioMed Central
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
Background Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance to therapy